You are here

ECC Symposium

The why, the which, and the how of targeting angiogenesis in GI malignancies

Official Sponsored Satellite Symposium at European Cancer Congress 2015 - Monday 28 September 2015

Angiogenesis plays an important role in the progression of gastrointestinal (GI) malignancies. Anti-angiogenic treatments have improved the overall survival of patients with these cancers. The introduction of new anti-angiogenic agents warrants both exploration of the latest clinical data and discussion on how treatments involving anti-angiogenic drugs can be used to optimize outcomes in this patient group.

Learning objectives of the symposium:

  • To understand the mechanisms and biology of angiogenesis in cancer
  • To be aware of the latest clinical trials investigating angiogenesis-targeting therapies in GI malignancies
  • To understand which therapies or treatment combinations produce optimal patient outcomes
  • To understand which patients would benefit from the latest developments, and how to optimize their management in daily clinical practice

 


Presentations

Search this site

Search form

ECCO2017 symposium webcast: Treatment evolution in advanced GI malignancies

Welcome and introduction - Florian Lordick

E-Alert

Subscribe to our E-Alert to keep up to date with the new items in the Resource Centre

Featured Content

New Book Content


This online Resource Centre has been sponsored by Lilly Oncology

Note that Lilly Oncology has no editorial control over the content of this Resource Centre. The Resource Centre and all content therein has been subject to an independent editorial review.

Share